Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.

• Revenue in USD (TTM)0.00
• Net income in USD-9.51m
• Incorporated2009
• Employees2.00

• Location
  Kintara Therapeutics Inc9920 Pacific Heights BlvdSuite 150, Suite 200SAN DIEGO 92121United StatesUSA
• Phone+1 (858) 350-4364
• Fax+1 (604) 202-1384
• Websitehttps://www.kintara.com/